Shareholders meeting
- Promoter holding remains stable at 64.02%.
- Established capacity in medical/bleached cotton (10,800 tonnes output capacity) with GOTS and GMP certifications.
- Trading below book value with P/B of 0.7x.
- Severe operational deterioration: TTM PAT of -₹11 Cr, negative ROCE of -3.0%, and operating margin falling to 0% in Mar 2026.
- Massive proposed leverage: Seeking authority to borrow up to ₹300 Cr (4.5x market cap) while currently struggling with ₹35 Cr debt.
- Governance & Capital Allocation: Plan to provide loans/guarantees up to ₹300 Cr to subsidiary Dhananya Capital and conduct material related-party transactions with Winsome Yarns Limited.
- Forex and commodity risks: Notional losses on forward contracts (₹10.99 Cr in Sep 2025) underline financial volatility.
- Material related-party transactions proposed with Winsome Yarns Limited
- Approval sought to provide guarantees/loans up to ₹300 Cr (3.3x net worth) to financial subsidiary Dhananya Capital Private Limited
- Forex derivative losses of ₹10.99 Cr on open forward contracts indicating weak treasury controls
Executive Summary & Catalyst Assessment
On July 28, 2026, Mohini Health & Hygiene Limited (MHHL) announced an Extraordinary General Meeting (EGM) to seek shareholder approval for increasing borrowing limits and mortgage charges to ₹300 Cr each. Additionally, the company seeks approval to pass guarantees/loans up to ₹300 Cr to its subsidiary, Dhananya Capital Private Limited (DCPL), and enter into material related-party transactions (RPT) with Winsome Yarns Limited (a proposed subsidiary of DCPL).
This announcement is a major red flag rather than a commercial growth catalyst. Raising debt limits to 4.5x current market cap (₹66 Cr) and 3.3x Net Worth (₹90 Cr) to fund a financial subsidiary and related parties while the core business is bleeding money presents substantial financial and governance risk.
Fundamental Quality & Earnings Trend
- Fundamental Grade: D (Deteriorating fundamentals, loss-making).
- Revenue Trend: Declining steadily from ₹101 Cr (Sep 2023) to ₹71 Cr (Mar 2026).
- Margin Contraction: OPM collapsed from ~8-9% in FY24 to 0.0% in Mar 2026. TTM OPM is 2.9%.
- Profitability: TTM PAT stands at -₹11 Cr (EPS -₹5.91). ROCE is -3.0%.
- Forex Risk: Company reported a notional loss of ₹10.99 Cr on open forward contracts as of Sep 2025.
Financial Impact Analysis
Since this announcement represents a corporate resolution for borrowing limits and loan guarantees rather than a commercial sales order: 1. Direct Revenue Uplift: 0% immediate commercial uplift. 2. Interest Cost Sensitivity: If MHHL draws even ₹100 Cr of the proposed ₹300 Cr borrowing limit at an estimated interest rate of 10-12%, annual interest expense would increase by ₹10-12 Cr. Given current TTM operating profit of ~₹9 Cr, additional interest costs would severely deepen net losses. 3. Capital Diversion Risk: Diverting capital/guarantees to Dhananya Capital (finance subsidiary) and Winsome Yarns away from core medical cotton operations increases structural bankruptcy/impairment risk.
Valuation & Scenario Framework
- Current Price: ₹35.5 (Market Cap ₹66 Cr, P/B 0.7x).
- Bull Case (15% upside to ₹40.8): Core operations recover to historical 8% OPM, debt expansion is non-dilutive and conservatively utilized, forex derivative losses cease.
- Base Case (-20% downside to ₹28.4): Core business stays near breakeven/minor loss, debt rises modestly, adding interest burden and depressing net worth.
- Bear Case (-50% downside to ₹17.8): High debt drawdown leads to severe interest burden, RPT/subsidiary defaults, and asset impairments.
Verdict Rationale
MHHL fails the quality gate due to negative ROCE (-3.0%) and ongoing operational losses. The proposed borrowing limit expansion to ₹300 Cr coupled with guarantees for related-party entities creates severe financial leverage and governance risks. Pursuant to research guardrails, governance and financial control concerns cap the rating to NO multibagger potential.
